←
foxtrot-study207 posts
foxtrot-study avatar

foxtrot-study

@FoxtrotStudy

Funder: Yorkshire Cancer Research. CIs: @jenseligmann, Dion Morton. Sponsor: University of Leeds. Collaborator: University of Birmingham. foxtrot@leeds.ac.uk

◷ Joined May 2019▧ 46 Photos and videos
foxtrot-study avatar
foxtrot-study@FoxtrotStudy·10 Jun 2024

Congratulations to Dr Niki Christou and the team in France who have randomised their first FOxTROT 2 participant! 🎉🎉🎉 I'm also pleased to announce that our Indian team have a total of 4 randomised participants! An amazing effort by both teams. 👏👏👏

Post attachment
foxtrot-study avatar
foxtrot-study@FoxtrotStudy·5 Jun 2024

Congratulations to the FOxTROT & ARIEL radiology support team for collecting 2 prestigious awards as top 20 presenters at the ESGAR, Gothenburg. 1st-time winner Dr James Platt delivered an analysis of the accuracy of CT scans for staging bowel cancer, funded by YCR.

Post attachment
Andrew Beggs avatar
⟳ foxtrot-study retweeted
Andrew Beggs@adbeggs·25 Feb 2024

Good article this, not just because it has @FoxtrotStudy in it! But still how often will we STILL have the argument in the MDT about giving NAC in colon cancer. Sigh.

BJS@BJSurgery25 Feb 2024

Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis ➡️ doi.org/10.1093/bjs/znae021 This systematic review and meta-analysis of seven studies involving 2120 patients with locally advanced colon cancer found that neoadjuvant chemotherapy is associated with a reduced hazard of recurrence and death, as well as improved 5-year overall survival and disease-free survival rates, compared with upfront surgery. No significant differences in perioperative complications or mortality were found, but neoadjuvant chemotherapy decreased the risk of incomplete resection. In conclusion, neoadjuvant chemotherapy appears to offer oncological benefits in the treatment of locally advanced colon cancer. Great work by @ClinicaNavarra - Daniel Aliseda, Jorge Arredondo, Carlos Sánchez-Justicia, Alicia Alvarellos, Javier Rodríguez, Ignacio Matos, Fernando Rotellar, Jorge Baixauli, Carlos Pastor #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @des_winter @evanscolorectal @robhinchliffe1 @bplwijn @ksoreide @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol #colorectalsurgery #StepUp4CRC @FightCRC @ACPGBI @Dukes_Club@ACPGBI_EduTrain@escp_tweets @YouESCP

Post attachmentPost attachment
Andrew Beggs avatar
⟳ foxtrot-study retweeted
Andrew Beggs@adbeggs·18 Jan 2024

A good article.. but let’s not forget @FoxtrotStudy had all comers enrolled at T3-4 N1/2 whereas HIPECT only enrolled T4 at baseline…

Our recent commentary of the HIPECT4 trial and current evidence for patients with advanced colon cancer ⁦@UHSurgOncology⁩ ⁦@UH_RE_Institute⁩ ⁦@AmmoriJohn⁩ ⁦@LukeRothermel ⁦@JordanMWinterMD⁩ @RonCharlesMD⁩ @doctorc369 acsjournals.onlinelibrary.wi…